Tuesday, Jul 5, 2005
South San Francisco, Calif. -- July 5, 2005 --Genentech, Inc. (NYSE:DNA) invites investors, the media and the general public to listen to an audio webcast discussing data presented at the 23rd Annual Meeting of the American Society of Retina Specialists (ASRS) in Montreal, Canada.
One-year data from clinical studies of Lucentis (ranibizumab) in patients with wet age-related macular degeneration will be presented at a mid-day session on July 18, 2005.
The webcast will begin at 1:30 p.m. Pacific Time on July 18, 2005 and will be archived until 5:00 p.m. Pacific Time on July 25, 2005. An audio telephone replay will also be available beginning at 5:00 p.m. Pacific Time on July 18, 2005 through 5:00 p.m. Pacific Time on July 25, 2005. Access numbers for this replay are: 1-800-642-1687 (U.S./Canada) and 1-706-645-9291 (international); Conference ID number is 7086270.
Genentech is a leading biotechnology company that discovers, develops, manufactures, and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from, or are based on, Genentech science. Genentech manufactures and commercializes multiple biotechnology products directly in the United States, and receives royalties or other income from companies that are licensed to market its products outside of the United States. The company has headquarters in South San Francisco, Calif., and is traded on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com.